Regurgitant volume to LA volume ratio in patients with secondary MR: the COAPT trial
- 7 December 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 25 (5) , 616-625
Abstract
The conceptual framework of proportionate versus disproportionate mitral regurgitation (MR) translates poorly to individual patients with heart failure (HF) and secondary MR. A novel index, the ratio of MR severity to left atrial volume (LAV), may identify patients with “disproportionate” MR and a higher risk of events. The objectives, therefore, were to investigate the prognostic impact of MR severity to LAV ratio on outcomes among HF patients with severe secondary MR randomized to transcatheter edge-to-edge repair (TEER) with the MitraClipTM device plus guideline-directed medical therapy (GDMT) vs. GDMT alone in the COAPT trial. The ratio of preprocedural regurgitant volume (RVol) to LAV was calculated from baseline transthoracic echocardiograms. The primary endpoint was 2-year covariate-adjusted rate of HF hospitalization (HFH). Among 567 patients, the median RVol/LAV was 0.67 (IQR 0.48-0.91). In patients randomized to GDMT alone, lower RVol/LAV was independently associated with an increased 2-year risk of HFH (adjHR: 1.77; 95% CI: 1.20-2.63). RVol/LAV was a stronger predictor of adverse outcomes than RVol or LAV alone. Treatment with TEER plus GDMT compared with GDMT alone was associated with lower 2-year rates of HFH both in patients with low and high RVol/LAV (Pinteraction = 0.28). Baseline RVol/LAV ratio was unrelated to 2-year mortality, health status, or functional capacity in either treatment group. Low RVol/LAV ratio was an independent predictor of 2-year HFH in HF patients with severe MR treated with GDMT alone in the COAPT trial. TEER improved outcomes regardless of baseline RVol/LAV ratio. Trial Name: Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial) (COAPT) ClinicalTrial.gov Identifier: NCT01626079 URL: https://clinicaltrials.gov/ct2/show/NCT01626079Keywords
Funding Information
- Abbott
This publication has 24 references indexed in Scilit:
- Guidelines for the Evaluation of Valvular Regurgitation After Percutaneous Valve Repair or ReplacementJournal of the American Society of Echocardiography, 2019
- Proportionate and Disproportionate Functional Mitral RegurgitationJACC: Cardiovascular Imaging, 2019
- Transcatheter Mitral-Valve Repair in Patients with Heart FailureNew England Journal of Medicine, 2018
- Percutaneous Repair or Medical Treatment for Secondary Mitral RegurgitationNew England Journal of Medicine, 2018
- Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trialAmerican Heart Journal, 2018
- Survival and Cardiovascular Outcomes of Patients With Secondary Mitral RegurgitationJAMA Cardiology, 2017
- Refining the prognostic impact of functional mitral regurgitation in chronic heart failureEuropean Heart Journal, 2017
- Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design PrinciplesJACC, 2015
- Left Atrial SizeJACC, 2006
- Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failureThe American Journal of Cardiology, 2003